Immuneering Corporation (IMRX) SEC News Jan. 20, 2026, 14:17 UTC 0 1 comments Director Schall Thomas J. 🟢 acquired 21.6K shares of Immuneering Corp (IMRX) at $4.67 Transaction Date: Jan 15, 2026 | Filing ID: 000014 Comment Full text
Hillstream BioPharma Inc. (was rebranding to Tharimmune Inc (THAR)) (HILS) SEC News Jan. 20, 2026, 14:06 UTC 3 0 comments New Form 424B5 - Tharimmune, Inc. Filed: 2026-01-20 AccNo: 0001493152-26-002773 Size: 578 KB Comment Full text
Interpace Biosciences, Inc. (IDXG) SEC News Jan. 20, 2026, 14:05 UTC 0 1 comments (10% Negative) Interpace Biosciences, Inc. (IDXG) Reports Q1 2026 Financial Results Comment Full text
RAPT Therapeutics Inc (RAPT) SEC News Jan. 20, 2026, 14:02 UTC 4 0 comments New Form SC TO-C - RAPT Therapeutics, Inc. Filed: 2026-01-20 AccNo: 0001193125-26-016042 Size: 70 KB Comment Full text
Tivic Health Systems Inc. (TIVC) SEC News Jan. 20, 2026, 14:00 UTC 0 1 comments (99% Neutral) Tivic Health Systems Inc. (TIVC) Provides Update on treatments for future operations Comment Full text
Vivani Medical Inc. (VANI) SEC News Jan. 20, 2026, 14:00 UTC 0 1 comments Director Williams Gregg 🟢 acquired 1.7M shares of Vivani Medical, Inc. (VANI) at $1.26 ($2.0M) Transaction Date: Jan 15, 2026 | Filing ID: 000145 Comment Full text
Synlogic Inc. (SYBX) SEC News Jan. 20, 2026, 14:00 UTC 0 1 comments (99% Neutral) Synlogic Inc. (SYBX) Files Form 8-K Comment Full text
Charles River Laboratories International Inc. (CRL) SEC News Jan. 20, 2026, 13:49 UTC 0 1 comments LaPlume Joseph W 🔴 sold 400 shares of CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL) at $163.72 Transaction Date: Aug 22, 2025 | Filing ID: 000002 Comment Full text
Oragenics Inc. (OGEN) SEC News Jan. 20, 2026, 13:30 UTC 0 1 comments (99% Neutral) Oragenics Inc. (OGEN) Files Form 8-K Comment Full text
Virios Therapeutics Inc. (VIRI) SEC News Jan. 20, 2026, 13:30 UTC 0 1 comments (99% Neutral) Virios Therapeutics Inc. (VIRI) Announces Enrollment Update for license Due to Patient Enrollment Issues, Manufacturing Considerations Comment Full text